Anti-inflammatory effect of a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor via the stimulation of heme oxygenase-1 in LPS-activated mice and J774.1 murine macrophages  by Park, Sung Bum et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 131 (2016) 241e250Contents lists availaJournal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperAnti-inﬂammatory effect of a selective 11b-hydroxysteroid
dehydrogenase type 1 inhibitor via the stimulation of heme
oxygenase-1 in LPS-activated mice and J774.1 murine macrophages
Sung Bum Park a, Ji Seon Park b, Won Hoon Jung a, Hee Youn Kim a, Hyun Jung Kwak a,
Jin Hee Ahn a, Kyoung-Jin Choi a, Yoon-Ju Na a, Sunhwa Choi a, Sang Dal Rhee a, c,
Ki Young Kim a, c, d, *
a Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong-gu, Daejeon 305-600, Republic of Korea
b Department of Human and Environmental Toxicology, University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon 305-333,
Republic of Korea
c Graduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 305-764,
Republic of Korea
d Department of Medicinal Chemistry and Pharmacology, University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon 305-333,
Republic of Koreaa r t i c l e i n f o
Article history:
Received 25 February 2016
Received in revised form
3 July 2016
Accepted 5 July 2016
Available online 16 July 2016
Keywords:
11b-Hydroxysteroid dehydrogenase type 1
Heme oxygenase-1
Lipopolysaccharide
Anti-inﬂammatory effect* Corresponding author. Bio & Drug Discovery Divis
of Chemical Technology, P.O. Box 107, Yuseong-gu, D
Korea. Fax: þ82 42 861 0770.
E-mail address: kykim@krict.re.kr (K.Y. Kim).
Peer review under responsibility of Japanese Pha
http://dx.doi.org/10.1016/j.jphs.2016.07.003
1347-8613/© 2016 The Authors. Production and hostin
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1) converts inactive cortisone to the active cortisol.
11b-HSD1 may be involved in the resolution of inﬂammation. In the present study, we investigate the
anti-inﬂammatory effects of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-
phenylethanone (KR-66344), a selective 11b-HSD1 inhibitor, in lipopolysaccharide (LPS)-activated
C57BL/6J mice and macrophages. LPS increased 11b-HSD1 activity and expression in macrophages,
which was inhibited by KR-66344. In addition, KR-66344 increased survival rate in LPS treated C57BL/6J
mice. HO-1 mRNA expression level was increased by KR-66344, and this effect was reversed by the HO
competitive inhibitor, ZnPP, in macrophages. Moreover, ZnPP reversed the suppression of ROS formation
and cell death induced by KR-66344. ZnPP also suppressed animal survival rate in LPS plus KR-66344
treated C57BL/6J mice. In the spleen of LPS-treated mice, KR-66344 prevented cell death via suppres-
sion of inﬂammation, followed by inhibition of ROS, iNOS and COX-2 expression. Furthermore, LPS
increased NFkB-p65 and MAPK phosphorylation, and these effects were abolished by pretreatment with
KR-66344. Taken together, KR-66344 protects against LPS-induced animal death and spleen injury by
inhibition of inﬂammation via induction of HO-1 and inhibition of 11b-HSD1 activity. Thus, we concluded
that the selective 11b-HSD1 inhibitor may provide a novel strategy in the prevention/treatment of in-
ﬂammatory disorders in patients.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Glucocorticoids are stress hormones that can exert a wide
spectrum of physiological effects by modulating immune andion, Korea Research Institute
aejeon 305-600, Republic of
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).inﬂammatory responses, and regulating energy metabolism, car-
diovascular homeostasis, and the stress response (1). Chronically-
elevated glucocorticoid levels are reliant on glucocorticoid pre-
receptor metabolism regulated by 11b-hydroxysteroid dehydroge-
nase 1 (11b-HSD1) rather than on circulating glucocorticoid levels
themselves (2). 11b-HSD1 is widely expressed and functions as an
endoplasmic reticulum-associated enzyme of an NADPH-
dependent oxoreductase, converting inactive cortisone to the
active glucocorticoid cortisol (3).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Effect of KR-66344 on 11b-HSD1 expression and inhibitory activity in LPS-
treated J774.1 macrophages. (A and B) 11b-HSD1 mRNA expression was determined
by RT-PCR and GAPDH was used as a control. Macrophages were incubated with
various concentrations of LPS (10e100 ng/ml) (A) and KR-66344 and CBX (B) for 24 h.
(C) The 11b-HSD1 inhibitory activity was determined using a cortisol concentration
assay. The 11b-HSD1 enzyme inhibitory activity is expressed as the mean ± S.E.M. of
two independent experiments performed in quadruplicate.
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integration of inﬂammatory and metabolic responses appear to
have potential for use as a therapeutic approach in the treatment of
inﬂammatory diseases and metabolic syndromes. Accordingly, the
possible involvement of 11b-HSD1 in the resolution of inﬂamma-
tion has been reported (4). Cytokines upregulate 11b-HSD1 activity
in inﬂammatory-responsive cells including macrophages (5,6), T, B,
and dendritic cells (5,7), and adipocytes (8). A selective 11b-HSD1
inhibitor inhibits obesity and inﬂammation in diet-induced obese
mice (9), and suppresses the expression of diabetes-regulating
genes (10). Thus, modulation of 11b-HSD1 activity selectively in
immune-inﬂammatory cells may present a new therapeutic strat-
egy for chronic inﬂammatory disease.
Heme oxygenase-1 (HO-1) is the inducible isoform of heme
oxygenase, which is a microsomal enzyme with the function of
oxidative degradationof heme (11). InductionofHO-1 in endothelial
cells protect against oxidative stress (12) and cilostazol suppressed
the production of anti-inﬂammatory cytokines and molecules via
the inhibition of NF-kB activation, through a mechanism involving
the up-regulation of cyclicAMP-dependent protein kinase
activation-coupled Nrf2-linked HO-1 expression in macrophages
(13). Thus, selective HO-1 induction may represent an adaptive
response that increases cellular resistance to inﬂammation.
In this study, we elucidate the anti-inﬂammatory effects of KR-
66344, a selective 11b-HSD1 inhibitor in LPS-treated murine J774.1
macrophages and C57BL/6J mice. KR-66344may provide protection
against LPS-induced cell death, animal death and spleen injury by
inhibiting inﬂammation through the decrease in ROS formation
and inﬂammatory cytokines release, followed by the inhibition of
NFkB-p65, ERK, JNK, and p38 MAPK phosphorylation, iNOS and
COX-2 expression, and induction of HO-1 expression as a result of
the inhibition of 11b-HSD1 activity and expression.
2. Materials and methods
2.1. Animals and drug administration
All animal experiments were carried out using 10-week-old
male C57BL/6J mice according to the Guidelines for Animal Experi-
mentation according to the established guidelines of the Institu-
tional Animal Care and Use committee of the Korea Research
Institute of Chemical Technology.
Three or four groups of 5 up to 10 mice were randomly divided
into: control, LPS, LPS plus KR-66344, and/or LPS plus KR-66344
and zinc protoporphyrin (ZnPP) groups. Mice were pretreated
with KR-66344 (30 mg/kg body weight, i.p.) or 30 mg/kg KR-66344
plus ZnPP (30 mg/kg body weight, i.p) for 2 h, followed by LPS (50
or 100 mg/kg, i.v.) treatment for 6 h (western blotting, PCR and
plasma NO analysis) or 3 days (animal survival analysis). Animals
were weighed regularly to allow accurate dosing.
2.2. Cell culture
Mouse reticulum cell sarcoma-derived J774.1 macrophages
(ATCC #TIB-67) were maintained in RPMI-1640 medium (Gibco/
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum,100 mg/ml penicillin, and 100 mg/ml streptomycin at 37 C in
5% CO2.
2.3. In vitro assay for 11b-HSD1 activity
Macrophages were seeded at a density of 2.5  104 cells/well
into 96-well plates, and incubated in medium containing 160 nM
cortisone, 20 nM NADPH and 50 ng/ml LPS in KR-66344 or carbe-
noxolone (CBX) for 24 h. Small aliquots of the reaction mixtureswere removed and subjected to a homogeneous time-resolved
ﬂuorescence cortisol assay in accordance with the manufacturer's
instructions (Nihon Schering, Tokyo, Japan). The IC50 values of the
compounds were determined from concentration-dependent in-
hibition curves using the GraphPad Prism software (GraphPad
Software Inc., La Jolla, CA).2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
Expression studies were carried out using gene-speciﬁc primers
for mouse 11b-HSD1, IL-6, IL-1b, HO-1, and GAPDH. All primers
were designed using the Primer 3 software (http://bioinfo.ut.ee/
primer3-0.4.0/). PCR primers for ampliﬁcation were designed
based on the following sequences: 11b-HSD1: sense, 50- ggga-
taattgacgccctagc-30; antisense, 50-tgaggcaggactgttctaag-30, IL-6:
sense, 50-agttgccttcttgggactga-30; antisense, 50-tgcacgatttcccaga-
gaac-30, IL-1b: sense, 50-caggcaggcagtatcactca-30; antisense, 50-
agctcatatgggtccgacag-30, HO-1: sense, 50- tccttgtaccatatctacacggcc-
Fig. 2. Effect of KR-66344 on animal survival rate in LPS-treated C57BL/6J mice. Three groups of 10 mice were randomly divided: control, LPS and LPS plus KR-66344. We were
administrated 50 mg/kg LPS and 30 mg/kg KR-66344 for 3 days. Animals were weighed regularly to allow accurate dosing.
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50-aactttggcattgtggaagg-30; antisense, 50-cacattgggggtaggaacac-30.
The cycling parameters were 95 C for 1 min, annealing at 54 C
(11b-HSD1, IL-1b, IL-6) and 56 C (HO-1) for 30 s, and an elongation
step at 72 C for 1 min, followed by a 10-min extension reaction at
72 C. The relative abundance of mRNA was calculated after
normalization to GAPDH.
2.5. Western blotting analysis
Spleen tissue was homogenated using homogenizer, and sub-
sequently treated with PRO-PREP protein extraction solution
(iNtRON Biotechnology Inc., Seoul, Korea). Spleen tissue homoge-
nate and cell lysates were centrifuged at 13,000 rpm, and 20 mg
protein of each sample was loaded onto NuPage Bis-Tris Mini Gels
(Invitrogen, Carlsbad, CA) and transferred to nitrocellulose mem-
branes (Amersham Biosciences, Piscataway, NJ). Following washing
in PBS, the blocked membranes were incubated with antibodies
against NFkB-p65, phospho-NFkB-p65, ERK 1/2, phospho-ERK1/2,
JNK, phospho-JNK, p38 MAPK, phospho-p38 MAPK, iNOS (Cell
Signaling Technology, MA, USA), COX-2, Bax, Bcl-2, and 11b-HSD1
(Santa Cruz Biotechnology, CA).
2.6. Cell viability assay
Cell viability was measured using the Cell Counting assay Kit-8
(CCK-8) (Dojindo Laboratories, Kumamoto, Japan). Macrophages
were treated with various concentrations of KR-66344 in
conjunctionwith LPS for 48 h 100 ml medium containing CCK-8 wasadded to cultured macrophages in 96-well plates and incubated for
4 h at 37 C, followed by the determination of absorbance at 450 nm
using a micro-plate spectrophotometer (BIO RAD, Inc., Korea).
2.7. Intracellular ROS and nitrite production assays
J774.1 macrophages were seeded at a density of 2.5  104 cells/
well in 96-well plates and grown to conﬂuence. Macrophages were
then exposed to various concentrations (0e20 mM) of KR-66344,
LPS, and with or without ZnPP for 24 h. We conducted the intra-
cellular ROS concentration assay according to Park and collabora-
tors (14). Intracellular ROS was indirectly measured through the
amount of free ﬂuorescent DCFH produced from nonﬂuorescent
20,70-dichloroﬂuorescin (DCFH) diacetate (Molecular Probes,
Eugene, OR). A Griess reagent assay was used to measure the nitrite
content. 50 ml culture medium or plasmawere mixed with an equal
amount of 1% sulfanilamide in 5% phosphoric acid, and incubated
for 10 min at room temperature. Subsequently, 50 ml 0.1% N-1-
naphthylethylenediamine dihydrochloride in water was added,
and incubated for a further 10 min. The absorbance was measured
at 540 nm using a microplate reader. The nitrite content was
calculated according to a NaNO2 standard curve.
2.8. Transfection of Stealth™ RNAi for 11b-HSD1 knockdown in
J774.1 macrophages
The 11b-HSD1 Stealth™ Select RNAi oligonucleotide (Target
Accessions no. NM_008288) was synthesized by Invitrogen
(Carsbad, CA). The stealth™ RNAi negative control Duplex
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Transfection efﬁciency was monitored using a ﬂuorescent oligo-
nucleotide (BLOCK-iT Fluorescent oligo, Invitrogen, Carsbad, CA)
and was estimated to be 80e90%.
Macrophages were transfected with 11b-HSD1 stealth™ RNAi
molecules using Lipofectamine RNAiMax according to Invitrogen's
protocols. A ﬁnal concentration of 100 nM 11b-HSD1 stealth™
select RNAi oligonucleotide was empirically determined to maxi-
mally suppress target RNA expression, and was transfected 48 h
prior to the treatment of compounds. The ability of the stealth™
RNAi oligonucleotide to knockdown 11b-HSD1 expression was
analyzed by Western blotting and RT-PCR on whole cell extracts.2.9. TUNEL staining
In situ nick-end labeling was performed, using a commercially
available kit (QIA33; Oncogene, Boston, MA) according to product
speciﬁcations, for the detection of cell death in spleen tissue.2.10. Statistics
The results are expressed as the mean ± S.E.M. Statistical sig-
niﬁcancewas determined by one-way analysis of variance (ANOVA)
followed by a Tukey's multiple-comparison test. P < 0.05 was
considered to be statistically signiﬁcant for all experiments.Fig. 4. Effect of KR-66344 and CBX on cell viability and ROS formation in 11b-HSD1-
knockdown J774.1 macrophages. Cells were treated with LPS and either KR-66344 or
CBX for 24 h (B) or 48 h (A), and subsequently the CCK-8 assay (A) and DCFH diacetate
staining (B) were performed. Values are expressed as the mean ± S.E.M. of two ex-
periments done in quadruplicate. ###P < 0.001 vs. control; ***P < 0.001 vs. LPS-treated
group; yP < 0.05, yyyP < 0.001 vs. negative control stealth RNAi transfected cells.3. Results
3.1. Effect of KR-66344 on 11b-HSD1 expression and activity in LPS-
treated J774.1 macrophages
11b-HSD1 mRNA expression increased in a concentration-
dependent manner with the maximal expression at 24 h post-
treatment with 50 ng/ml LPS (Fig. 1A). The increased 11b-HSD1
mRNA expression by LPS was reduced by treatment with 20 mMKR-
66344 for 24 h (Fig. 1B). CBX, a non-selective 11b-HSD1 inhibitor,
also inhibited the 11b-HSD1mRNA expression in LPS-treated J774.1
macrophages. Furthermore, when the 11b-HSD1 enzyme activity
was assayed after incubation with KR-66344 for 24 h in macro-
phages, the oxoreductase activity of 11b-HSD1 was signiﬁcantly
inhibited in a concentration-dependent manner with an IC50 of
890 nM (Fig. 1C).3.2. Effect of KR-66344 on survival in LPS-treated C57BL/6J mice
We treated mice with high dose of LPS (50mg/kg) intravenously
to create a lethal tissue injury model. Such dosage of LPS can cause
over 50% reduced survival rate after 1 day. The survival rate was
assessed for 3 days. As shown in Fig. 2B, all mice treated with LPS
died within 3 days, but KR-66344 treated mice had a 20% survival
rate.Fig. 3. Effect of KR-66344 and ZnPP on HO-1 expression and on the anti-inﬂammatory and
dependency effect of KR-66344 on the induction of the HO-1 protein in LPS treated J774.1 m
and HO-1 protein expression was determined by western blotting. (B) Effect of ZnPP on HO-
with the indicated concentrations of ZnPP (0.1e1 mM), LPS (50 ng/ml) and KR-66344 (10 m
sequently measured by RT-PCR. (C and D) Effect of ZnPP on cell viability and ROS format
experiments performed in quadruplicate. (E) Effect of ZnPP on KR-66344 induced animal s
control, LPS, LPS plus KR-66344, and LPS plus KR-66344 and ZnPP. We were administrated 10
regularly to allow accurate dosing. (F) Effect of ZnPP on KR-66344 induced HO-1 over-expre
ZnPP (30 mg/kg body weight, i.p.) for 2 h, followed by LPS (30 mg/kg, i.v.) treatment for 6 h 1
mean ± S.E.M. of three experiments. #P < 0.05, ###P < 0.001 vs. control; **P < 0.01,***P < 0.0
group.3.3. Effect of KR-66344 on the expression of HO-1 in LPS-induced
inﬂammation
Following treatment with 10 mM KR-66344, HO-1 mRNA
expression increased in a time-dependent manner with maximal
expression at 4 h (Supplementary Fig. 1A). Furthermore, KR-66344
increased the HO-1 mRNA expression in a concentration-
dependent manner with maximal expression at 10 mM in macro-
phages (Supplementary Fig. 1B). HO-1 protein expression by KR-
66344 increased in a time-dependent manner with the maximal
expression at 8 h in macrophages (Fig. 3A).
To conﬁrm the role of HO-1 upregulation by KR-66344, we
examined the effects of ZnPP, a HO-1 competitive inhibitor, on LPS-
induced cell death and ROS formation in macrophages. The HO-1anti-apoptotic actions in LPS-treated J774.1 macrophages and C57BL/6J mice. (A) Time
acrophages. Macrophages were also incubated at the indicated times with KR-66344,
1 expression in LPS and KR-66344 treated macrophages. Macrophages were incubated
M) or CBX (20 mM) for 4 h (B), 24 h (D) or 48 h (C). HO-1 mRNA expression was sub-
ion in macrophages. Values are expressed as the mean ± S.E.M. of two independent
urvival in LPS treated C57BL/6J mice. Four groups of 10 mice were randomly divided:
0 mg/kg LPS, 30 mg/kg KR-66344 and 30 mg/kg ZnPP for 3 days. Animals were weighed
ssion in spleens of LPS-treated C57BL/6J mice. Mice were pretreated with KR-66344 or
1b-HSD1 and HO-1 expressions was determined by RT-PCR. Values are expressed as the
01 vs. LPS-treated group; yyP < 0.01, yyyP < 0.001 vs. LPS plus KR-66344 or CBX-treated
Fig. 5. Effect of KR-66344 on LPS-induced apoptosis in the spleens of C57BL/6J mice. Four groups of 5 mice were randomly divided into control, LPS, LPS plus KR-66344, and LPS plus
KR-66344 and ZnPP for western blotting analysis. Mice were pretreated with KR-66344 (30 mg/kg body weight, i.p.) or 30 mg/kg KR-66344 plus ZnPP (30 mg/kg body weight, i.p)
for 2 h, followed by LPS (30 mg/kg, i.v.) treatment for 6 h (A) TUNEL analysis. (B) Western blotting. Result of Bax and Bcl-2 ratio was expressed as the mean ± S.E.M. ##P < 0.01 vs.
control; *P < 0.05 vs. LPS-treated group; yyP < 0.01 vs. LPS plus KR-66344- treated group.
S.B. Park et al. / Journal of Pharmacological Sciences 131 (2016) 241e250246mRNA expression level was increased by 10 mM KR-66344, and this
effect was reversed by 1 mM ZnPP in murine macrophages (Fig. 3B).
Furthermore, the suppressed cell death and ROS formation caused
by KR-66344 (10 mM) and CBX (20 mM) was signiﬁcantly reversed
by pretreatment with ZnPP (1 mM) in macrophages (Fig. 3C and D).
As shown in Fig. 3E, in vivo animal survival test, ZnPP reversed the
protective effect of KR-66344 against LPS treated mice. As in vitro
studies of HO-1 upregulation by KR-66344, in the spleens of LPS-
treated mice, treatment with KR-66344 also induced a marked
increase in HO-1 mRNA expression (Fig. 3F). Furthermore, the
increased 11b-HSD1 mRNA expression by LPS was reduced by
treatment with KR-66344 for 24 h (Fig. 3F). These results were
signiﬁcantly reversed by pretreatment with ZnPP (30 mg/kg).3.4. Anti-inﬂammatory effect of KR-66344 by 11b-HSD1
knockdown in J774.1 macrophages
Transfection of the 11b-HSD1 RNAi oligonucleotide in macro-
phages resulted in the reduction of 11b-HSD1 protein expression to80% of the control levels (Supplementary Fig. 2). As shown in Fig. 4A,
cell death was signiﬁcantly reduced by 11b-HSD1 knockdown, and
the inhibition of the 11b-HSD1 protein itself mimicked the anti-
apoptotic effects of KR-66344 in 11b-HSD1 RNAi transfected cells,
and was not further enhanced by the presence of KR-66344.
Furthermore, ROS formation was signiﬁcantly reduced by 11b-HSD1
knockdown in LPS-treated macrophages, and KR-66344 did not
inhibit theROS formation in11b-HSD1RNAi transfectedcells (Fig.4B).3.5. Effects of KR-66344 on LPS-induced cell death and spleen
injury
The effects of KR-66344 on LPS-induced cell death were deter-
mined by the TUNEL assay and the expression of Bcl-2 and Bax in
the spleen of C57BL/6J mice (Fig. 5A and B). The number of TUNEL-
positive cells signiﬁcantly increased in the spleens of LPS-treated
mice, which was markedly reduced after treatment with 30 mg/
kg KR-66344 (Fig. 5A). Furthermore, KR-66344 elevated Bcl-2
expression and suppressed Bax expression in the spleens of mice.
Fig. 6. Effect of KR-66344 on LPS-induced ROS formation, and iNOS and COX-2 expression in plasma and spleens of C57BL/6J mice. Three groups of 7 mice were randomly divided
into control, LPS, and LPS plus KR-66344 for ROS formation in plasma (A and B). Subsequently, nitrite concentration (A) and ROS formation (B) in plasma were determined by a
Griess reagent assay and a DCFH diacetate staining assay. (C) Four groups of 5 mice were randomly divided into control, LPS, LPS plus KR-66344, and LPS plus KR-66344 and ZnPP for
western blotting analysis. Mice were pretreated with KR-66344 (30 mg/kg body weight, i.p.) or 30 mg/kg KR-66344 plus ZnPP (30 mg/kg body weight, i.p) for 2 h, followed by LPS
(30 mg/kg, i.v.) treatment for 6 h. Values are expressed as the mean ± S.E.M. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. control; **P < 0.01, ***P < 0.001 vs. LPS-treated group; yP < 0.05,
yyP < 0.01 vs. LPS plus KR-66344- treated group.
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treatment with ZnPP (30 mg/kg).
Consistent with this observation, when macrophages were
incubated in media containing 50 ng/ml LPS for 2 days, cell
viability was inhibited to 62.6 ± 0.5% of the control. KR-66344
(0.1e20 mM) suppressed the cell death caused by 50 ng/ml
LPS in a concentration-dependent manner (Supplementary
Fig. 3).3.6. Effects of KR-66344 on nitrite and ROS formation in the spleens
of LPS-treated C57BL/6J mice
LPS signiﬁcantly increased the nitrite and ROS formation, and
treatment with 30 mg/kg KR-66344 suppressed this effect
(Fig. 6A and B). Furthermore, treatment with KR-66344
inhibited the over-expression of iNOS and COX-2 caused by LPS
(Fig. 6C).
Consistent with these ﬁndings, LPS increased the nitrites con-
centration (724.2 ± 101.4% of the control) and ROS formation
(191.3 ± 12.7% of the control) in J774.1 macrophages
(Supplementary Fig. 4A and B). KR-66344 suppressed the nitrite
and ROS formation caused by LPS. CBX also suppressed the LPS-
induced nitrite and ROS formation, and cell death in macrophages
(Supplementary Figs. 3,4A and B). Moreover, KR-66344 inhibited
the over-expression of iNOS and COX-2 caused by LPS in macro-
phages (Supplementary Fig. 4C).3.7. Effects of KR-66344 on the induction of inﬂammatory cytokines
by LPS
Spleens of C57BL/6J mice treated with LPS (100 mg/kg) showed
increased IL-1b and IL-6 mRNA expression. This effect was abol-
ished by KR-66344 pre-treatment, and ZnPP reversed the protec-
tive effect of KR-66344 (Fig. 7A). Using the same in vitromodel, we
measured the LPS-induced inﬂammatory cytokine expression by
KR-66344 using RT-PCR (Supplementary Fig. 5A). The pro-
inﬂammatory cytokine mRNA expression increased in a
concentration-dependent manner with the maximal expression at
24 h post-treatment with 50 ng/ml LPS (data not shown). The
increased pro-inﬂammatory cytokine mRNA expression caused by
LPS was reduced after treatment with KR-66344 and CBX for 24 h
(Supplementary Fig. 5A).
3.8. Effects of KR-66344 on LPS-mediated signaling pathways
LPS treatment markedly increased NFkB-p65 and MAPK
phosphorylation, and this effect was abolished by treatment with
KR-66344 (Fig. 7B). However, the protective effect of KR-66344
was signiﬁcantly reversed by ZnPP. Using the same in vitro
model, in macrophages, treatment with 50 ng/ml LPS increased
NFkB-p65 and MAPK phosphorylation when assessed after
120 min (data not shown). This effect was abolished by co-
incubation with KR-66344 in a concentration-dependent
manner (Supplementary Fig. 5B).
Fig. 7. Effect of KR-66344 on LPS-mediated pro-inﬂammatory cytokine expression and signaling pathway in the spleens of C57BL/6J mice. Four groups of 5 mice were randomly
divided into control, LPS, LPS plus KR-66344, and LPS plus KR-66344 and ZnPP. Mice were pretreated with KR-66344 (30 mg/kg body weight, i.p.) or 30 mg/kg KR-66344 plus ZnPP
(30 mg/kg body weight, i.p) for 2 h, followed by LPS (30 mg/kg, i.v.) treatment for 6 h. Values are expressed as the mean ± S.E.M. ##P < 0.01, ###P < 0.001 vs. control; *P < 0.05 vs.
LPS-treated group; yP < 0.05 vs. LPS plus KR-66344- treated group.
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Septic shock is a life-threatening complication of infections (15).
Excessive systemic inﬂammation in sepsis is the most common
cause of death in intensive care units (16), ultimately resulting in
multiple organ dysfunction syndrome (17). Genetic mouse models
have been used to illustrate the relationships between 11b-HSD1
and anti-inﬂammatory responses. It has been demonstrated that
11b-HSD1-knockout mice delay the acquisition of phagocytic ca-
pacity in macrophages and possess increased numbers of free
apoptotic neutrophils (6). Histological evaluation has suggested
that 11b-HSD1-deﬁcient mice have a more severe inﬂammatory
response (18), and accordingly, a number of 11b-HSD1 inhibitors
have shown anti-inﬂammatory efﬁcacy in rodent models.
In our previous study, we reported that KR-66344, 2-(3-
benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-
phenylethanone, acted as a selective 11b-HSD1 inhibitor (19). Here,
KR-66344 inhibits the 11b-HSD1 activity with IC50 value (890 nM)
in LPS treated J774.1 macrophages. The 11b-HSD1mRNA expression
and cortisol concentration (data not shown) increased in a dose-
dependent manner with the maximal expression at 24 h post-
treatment with 50 ng/ml LPS. This increased 11b-HSD1 mRNA
expression caused by LPSwas reduced by treatment with KR-66344
for 24 h. CBX, a non-selective 11b-HSD1 inhibitor, also inhibited the
11b-HSD1 mRNA expression in LPS-treated macrophages.Furthermore, in animal survival test, all mice treated with LPS died
within 3 days, but KR-66344 treated mice had a 20% survival rate. It
suggests that KR-66344 could attenuate septic shock in LPS treated
mice via inhibition of 11b-HSD1 activity and expression.
HO-1 has recently been reported to be associated with chronic
diseases that are activated by oxidative/inﬂammatory actions (20).
HO-1 expression is induced ubiquitously in response to oxidative
stress, which has been shown to reduce the programmed cell death
induced by ischemia/reperfusion (21), and to protect against
cytotoxic agonists such as TNF, lymphotoxin, or Fas (22). Moreover,
inﬂammation is regulated by the HO-1 system, which plays an
essential role in cellular homeostasis (23). Following treatment
with KR-66344, the HO-1 mRNA expression increased in a time-
dependent manner with the maximal expression at 4 h and
increased the HO-1 mRNA expression in a concentration-
dependent manner with the maximal expression at 10 mM in
macrophages. The HO-1 protein expression increased in a time-
dependent manner with the maximal expression at 8 h in macro-
phages. To conﬁrm the role of HO-1 up-regulation by KR-66344, we
examined the effects of ZnPP, a speciﬁc HO-1 competitive inhibitor,
on LPS-induced cell death and ROS formation in macrophages. The
HO-1 mRNA expression level was increased by KR-66344, and this
effect was reversed by ZnPP in murine macrophages. Furthermore,
the suppressed cell death and ROS formation by KR-66344 and CBX
was signiﬁcantly reversed by pretreatment with ZnPP in
S.B. Park et al. / Journal of Pharmacological Sciences 131 (2016) 241e250 249macrophages. Additionally, in vivo animal survival test, ZnPP
(30 mg/kg) reversed the protective effect of KR-66344 against LPS
induced animal death. In the spleens of LPS-treated mice, treat-
ment with KR-66344 also induced a marked increase in HO-1
mRNA expression and inhibition of 11b-HSD1 mRNA expression.
These results were reversed by ZnPP treatment (30 mg/kg). Thus,
these results demonstrate that HO-1 upregulation plays a pivotal
role in the anti-inﬂammatory action of KR-66344 in LPS-treated
macrophages and mice. To further understand the role of 11b-
HSD1 in the anti-inﬂammatory action of KR-66344, we examined
the inﬂuence of 11b-HSD1 knockdown on LPS-stimulated cell death
and ROS formation in macrophages. As shown in result, cell death
and ROS formation caused by LPS was signiﬁcantly reduced by 11b-
HSD1 knockdown, and the inhibition of the 11b-HSD1 protein itself
mimicked the anti-apoptotic effects of KR-66344 in 11b-HSD1
RNAi-transfected cells, which was not further enhanced by the
presence of KR-66344. These results demonstrate that 11b-HSD1
inhibition plays a pivotal role in the anti-inﬂammatory action of KR-
66344 in LPS-treated macrophages and spleens of mice.
Oxidative stress induces the stress-activated signaling pathway,
producing cytokines and aggravating inﬂammatory activity in the
liver and spleen (24). This in turn provokes progression towards
non-alcoholic steatohepatitis via the induction of lipid peroxida-
tion, injury, and inﬂammation (25). The pro-inﬂammatory cyto-
kines play an integral role in the development of non-alcoholic
steatohepatitis through the stimulation of hepatic lipogenesis and
adipose lipolysis, triggering mitochondrial dysfunction and oxida-
tive stress, thus inducing tissue injury and cell death (26). Addi-
tionally, a selective COX-2 inhibitor induced HO-1 expression,
contributing to ROS production and the activation of MAPK in
macrophages (27). Consistent with these observations, inhibition of
DNA fragmentation by KR-66344 was accompanied by elevated
anti-apoptotic Bcl-2 and decreased pro-apoptotic Bax expression in
the spleens of LPS-treated mice. Furthermore, KR-66344 inhibited
the nitrite and ROS formation in LPS-activated macrophages and in
the plasma of mice. In addition, the levels of iNOS and COX-2
proteins were markedly upregulated by LPS, which was sup-
pressed by treatment with KR-66344.
LPS has been shown tomarkedly increase the expression of pro-
inﬂammatory cytokines in addition to 11b-HSD1 reductase activity
(28). Moreover, 11b-HSD1 intensiﬁed the NF-kB and MAPK
signaling pathways in activated preadipocytes (29). In this study,
inﬂammatory cytokine gene expression such as IL-1b and IL-6 was
signiﬁcantly increased in the spleen of LPS-treatedmice, which was
markedly reduced by treatment with KR-66344. Furthermore, KR-
66344 suppressed the MAPK signaling cascades in the spleen of
mice caused by LPS. Consistent with these ﬁndings, KR-66344, in
LPS-activated macrophages, signiﬁcantly suppressed secretion of
TNF-a, IL-6, and MCP-1 in a concentration-dependent manner, and
suppressed the MAPK signaling cascades in the LPS-activated
macrophages. These results support the notion that the suppres-
sion of inﬂammatory cytokine expression and ROS production is a
key mechanism of the KR-66344-induced anti-inﬂammatory and
anti-apoptotic effects.5. Conclusions
KR-66344 provided protection against LPS-inducedmacrophage
or animal death and spleen injury by the inhibition of inﬂammation
via the induction of HO-1 expression and the inhibition of 11b-
HSD1 activity and expression. It is concluded that the selective 11b-
HSD1 inhibitor may provide a novel strategy, without toxicity, in
the prevention and treatment of inﬂammatory disorders in patients
with endotoxic shock.Conﬂict of interest
None declared.Acknowledgements
We would like to acknowledge the ﬁnancial support from the
R&DConvergence ProgramofNational Research Council of Science&
Technology (CCP-15-20-KRICT), the Center for Biological Modulators
of the 21st Century Frontier R&D program, Ministry of Science and
Technology (CBM34-A1100-00-00-00), and the project of the Korea
Research Institute of Chemical Technology, theMinistry if Knowledge
Economy (SI1606-01), Republic of Korea.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2016.07.003.References
(1) Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al.
A transgenic model of visceral obesity and the metabolic syndrome. Science.
2001;294:2166e2170.
(2) Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN,
et al. A novel selective 11b-hydroxysteroid dehydrogenase type 1 inhibitor
prevents human adipogenesis. J Endocrinol. 2008;197:297e307.
(3) Dzyakanchuk AA, Balazs Z, Nashev LG, Amrein KE, Odermatt A. 11beta-
Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high
ratio of NADPH/NADP(þ) and is stimulated by extracellular glucose. Mol Cell
Endocrinol. 2009;301:137e141.
(4) Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR. Local
ampliﬁcation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase
type 1 and its role in the inﬂammatory response. Ann N Y Acad Sci.
2006;1088:265e273.
(5) Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, et al. 11 Beta-
hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon
differentiation to macrophages. J Immunol. 2001;167:30e35.
(6) Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, et al. Local
ampliﬁcation of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase
type 1 promotes macrophage phagocytosis of apoptotic leukocytes.
J Immunol. 2006;176:7605e7611.
(7) Freeman L, Hewison M, Hughes SV, Evans KN, Hardie D, Means TK, et al.
Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regula-
tion of glucocorticoid bioavailability by human dendritic cells. Blood.
2005;106:2042e2049.
(8) Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, et al.
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in
adipose tissue: tissue-speciﬁc induction by cytokines. Endocrinology.
2001;142:1982e1989.
(9) Wang L, Liu J, Zhang A, Cheng P, Zhang X, Lv S, et al. BVT.2733, a selective 11b-
hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and
inﬂammation in diet-induced obese mice. PLoS One. 2012;7:e40056.
(10) Shin KM, Shen L, Park SJ, Jeong JH, Lee KT. Bis-(3-hydroxyphenyl) diselenide
inhibits LPS-stimulated iNOS and COX-2 expression in RAW 264.7 macro-
phage cells through the NF-kappaB inactivation. J Pharm Pharmacol. 2009;61:
479e486.
(11) Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to
bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A. 1968;61:
748e755.
(12) Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ. Endothelial
heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-
oxide synthase and S-nitrosothiols. J Biol Chem. 2000;275:13613e13620.
(13) Park SY, Lee SW, Baek SH, Lee SJ, Lee WS, Rhim BY, et al. Induction of heme
oxygenase-1 expression by cilostazol contributes to its anti-inﬂammatory
effects in J774 murine macrophages. Immunol Lett. 2011;136:138e145.
(14) Park SB, Jung WH, Kang NS, Park JS, Bae GH, Kim HY, et al. Anti-diabetic and
anti-inﬂammatory effect of a novel selective 11b-HSD1 inhibitor in the diet-
induced obese mice. Eur J Pharmacol. 2013;721:70e79.
(15) Gonzalez-Rey E, Chorny A, Robledo G, Delgado M. Cortistatin, a new anti-
inﬂammatory peptide with therapeutic effect on lethal endotoxemia. J Exp
Med. 2006;203:563e571.
(16) Johnson D, Mayers I. Multiple organ dysfunction syndrome: a narrative re-
view. Can J Anaesth. 2001;48:502e509.
(17) Baue AE, Durham R, Faist E. Systemic inﬂammatory response syndrome (SIRS),
multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF):
are we winning the battle? Shock. 1998;10:79e89.
S.B. Park et al. / Journal of Pharmacological Sciences 131 (2016) 241e250250(18) Schmidt M, Weidler C, Naumann H, Anders S, Sch€olmerich J, Straub RH.
Reduced capacity for the reactivation of glucocorticoids in rheumatoid
arthritis synovial cells: possible role of the sympathetic nervous system?
Arthritis Rheum. 2005;52:1711e1720.
(19) Park JS, Rhee SD, Kang NS, Jung WH, Kim HY, Kim JH, et al. Anti-diabetic and
anti-adipogenic effects of a novel selective 11b-hydroxysteroid dehydroge-
nase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-
benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem Pharmacol.
2011;81:1028e1035.
(20) Ndisang JF. Role of heme oxygenase in inﬂammation, insulin-signalling, dia-
betes and obesity. Mediators Inﬂamm. 2010;2010:359732.
(21) Krüger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, et al. Donor Toll-
like receptor 4 contributes to ischemia and reperfusion injury following hu-
man kidney transplantation. Proc Natl Acad Sci U S A. 2009;106:3390e3395.
(22) Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP.
Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev
Immunol. 1999;17:331e367.
(23) Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a
novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell
Mol Biol. 1966;15:9e19.(24) Evans JL, Goldﬁne ID, Maddux BA, Grodsky GM. Oxidative stress and stress-
activated signaling pathways: a unifying hypothesis of type 2 diabetes.
Endocr Rev. 2002;23:599e622.
(25) Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where
are we going? Gut. 2002;50:585e588.
(26) Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty
liver and disease progression to steatohepatitis: implications for treatment.
Am J Gastroenterol. 2008;10:1036e1042.
(27) Wang JS, Ho FM, Kang HC, Lin WW, Huang KC. Celecoxib induces heme
oxygenase-1 expression in macrophages and vascular smooth muscle cells via
ROS-dependent signaling pathway. Naunyn Schmiedebergs Arch Pharmacol.
2011;383:159e168.
(28) Ishii T, Masuzaki H, Tanaka T, Arai N, Yasue S, Kobayashi N, et al. Augmen-
tation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1
macrophages-role of 11beta-HSD1 in pro-inﬂammatory properties in mac-
rophages. FEBS Lett. 2007;581:349e354.
(29) Ishii-Yonemoto T, Masuzaki H, Yasue S, Okada S, Kozuka C, Tanaka T, et al.
Glucocorticoid reampliﬁcation within cells intensiﬁes NF-kappaB and MAPK
signaling and reinforces inﬂammation in activated preadipocytes. Am J
Physiol Endocrinol Metab. 2010;298:E930eE940.
